Medicare’s ESA Proposal Relies Too Much On Off-Label Data, Amgen Says

CMS improperly applies safety data from off-label uses of erythropoiesis-stimulating agents to chemotherapy-induced anemia in its recent proposed national coverage determination on ESAs, Amgen maintains

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet